SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc ($HIMS) is trending after withdrawing its compounded GLP-1 weight-loss pill following FDA warnings and legal pressure, causing a notable stock decline. The community is sharply divided, with bears denouncing the company's practices and forecasting further drops, while bulls perceive the withdrawal as a strategic move to mitigate risk and anticipate a rebound for its broader telehealth platform.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending as news of an extended $250 million capital runway through 2028 and a new cotton traceability collaboration fuels intense debate among investors. While many anticipate a significant short squeeze given its low float and history of parabolic moves, others express caution over potential dilution and view the rally as speculative.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to high anticipation for its imminent Q4 earnings report, with the community actively debating its 'undervalued' status and potential for a short squeeze. Investors are optimistic that strong results, backed by its AI-driven lending model, could finally align the stock price with its perceived strong fundamentals.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a mixed financial report, where solid past performance was tempered by a conservative revenue outlook, exacerbating community debate over the company's valuation and the broader SaaS sector's vulnerability to AI advancements. Many investors are weighing whether the stock is an oversold opportunity or if headwinds, including perceived unutilized buybacks, suggest further pressure on the work management software provider.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending after its strategic acquisition of AI vision firm StereoLabs, which the community views as a smart move that expands its unified digital lidar and software platform to offer a complete perception solution for physical AI across diverse applications. This pivotal deal reinforces Ouster's path to profitability and leadership in sectors like robotics, industrial, and smart infrastructure, amidst ongoing discussions about its strong financials and undervalued status.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending sharply after Morgan Stanley initiated coverage with a bullish $37 price target, recognizing its strategic expansion into AI/HPC data centers and recent acquisition of new power generation sites. The community is actively discussing WULF's strong infrastructure play and significant partnership with Google, solidifying its position beyond traditional Bitcoin mining amid high AI demand.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is generating significant conversation following its Q4 '25 earnings, which reported a loss but offered 2026 cost reduction guidance, compounded by intense community speculation surrounding a potential strategic partnership with POSCO. Investors remain sharply divided, with many bullish on high HRC steel prices and expiring unfavorable contracts, while others express skepticism over past performance and recent share dilution in the context of broader US steel tariffs.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing notable upward price movement as the community discusses its "Eagle Line" inauguration, viewing it as a pivotal step toward scalable solid-state battery production and potential OEM partnerships, all while anticipating its upcoming earnings report for further commercialization updates.

Republic Airways Holdings, Inc. is a holding company that engages in the provision of passenger airline services. The airlines provide fixed-fee flights operated under their codeshare partners brands: American Eagle, Delta Connection, and United Express. The company was founded in 1974 and is headquartered in Indianapolis, IN.

Republic Airways Holdings Inc.

RJET is trending amid intense community discussion following the Mesa merger, which sees major carriers now as owners, fundamentally altering future contracts and sparking deep value interest. However, recent escrow share distribution from the merger is drawing significant criticism, with many feeling common shareholders received negligible benefit compared to larger stakeholders.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after a significant stock drop, fueled by a short-seller's report alleging financial improprieties and concerns over a projected revenue decline, even as the company denies the claims and maintains a strategy of improving margins through strategic partnerships in AI and cloud. The community is actively debating if the sell-off is an overreaction, pointing to strong analyst targets and the ongoing business transformation for long-term value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>XTL will acquire NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million. &nbsp;</li><li>NeuroNOS is a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD) and other neurodevelopmental and neurodegenerative disorders.&nbsp;</li><li>NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.</li></ul>Shares of Beyond Air, Inc. (XAIR) rallied 149% on Tuesday after XTL Biopharmaceuticals Ltd. (XTLB) announced a deal to acquire a majority stake in its subsidiary NeuroNOS Ltd.Under the deal, IP portfolio company XTL will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.beyondair.net/news-events/press-releases?i=161064">acquire</a> 85% of NeuroNOS, a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD), and other neurodevelopmental and neurodegenerative disorders.Shares of XTLB gained 51% at the time of writing.<h2 class="st-heading-2">Deal Terms</h2>As part of the deal, XTL will acquire 85% of NeuroNOS for 19.9% of XTL's issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million.XTL noted that NeuroNOS's drug development platform is designed to address the underlying molecular mechanisms driving autism unlike treatments based on behavioral symptoms. NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.According to BeyondAir, autism spectrum disorder affects about one in 31 children in the U.S. and has been rising dramatically. No FDA-approved therapies aimed at disease modification exist for the disorder at present.The company also noted that the Trump administration has, in recent times, emphasized support for new medicines aimed at treating autism.“The administration has allocated $50 million in new NIH funding for autism research initiatives. This recognition at the federal level signals a fundamental shift in regulatory priorities and resource allocation toward autism research and treatment development,” BeyondAir said in a statement.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around XAIR and XTLB rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user applauded the deal, opining that selling most of the unit will help de-risk Beyond Air’s investment while also creating potential future revenue streams.<stembedurl>https://www.stocktwits.com/stockpro2010/message/641694012</stembedurl><a href="https://stocktwits.com/symbol/XAIR">XAIR stock</a> has fallen 70% this year while <a href="https://stocktwits.com/symbol/XTLB">XTLB</a> dropped 44% in the same period.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/travere-therapeutics-stock-slumps-after-fda-extends-drug-review-timeline-to-april/cmUXhZuR4IK">Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

XAIR Stock More Than Doubled Today — What’s Driving The Rally?

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.

Equity

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.


Beyond Air Names Dan Moorhead CFO

(RTTNews) - Beyond Air, Inc. (XAIR), a commercial-stage medical device and biopharmaceutical company, on Tuesday announced that it has appointed Dan Moorhead as Chief Financial Officer, effective...

Chagee Holdings, Tilray Brands And 3 Stocks To Watch Heading Into Friday

US stock futures higher. Chagee Holdings, Tilray Brands, Globus Maritime, Post Holdings, and Beyond Air in focus.read more...

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

Beyond Air (XAIR) delivered earnings and revenue surprises of -2.00% and -1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +29.41% and +146.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Beyond Air (XAIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates

Medical device company Beyond Air ($XAIR) stock was down 9.8% on Tuesday morning (9:49 a.m. ET) after the company’s second-quarter revenues fell short of analyst estimates, pushing retail sentiment down.The biopharma company’s earnings per share (EPS) were in line with analyst estimates of -$0.28.However, its revenue came in at $798,000, falling short of consensus estimates of about $1.08 million. Net loss narrowed to $14.3 million compared to $17.4 million in the same period last year.“Our commercial strategy continued to drive results throughout the quarter with our total number of customers increasing by over 60%,” Steve Lisi, CEO of Beyond Air, said in a statement. “We believe this is just the beginning of a pivotal year for our company as we leverage our expanding network of reference customers that have implemented LungFit PH in their hospitals.”Retail sentiment on the stock turned ‘extremely bullish’ from ‘bullish’ a day ago. The accompanying message volumes were in the ‘high’ zone on Tuesday.<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_12_at_8_18_04_PM_25a6267991.png" alt="Screenshot 2024-11-12 at 8.18.04 PM.png" width="1300" height="290"><figcaption>XAIR Sentiment and Message Volume on Nov 12 as of 9:47 a.m. ET | Source: Stocktwits</figcaption></figure>Beyond Air, which is focused on developing treatments for lung diseases, has also completed a $20.6 million private placement offering with “multiple healthcare-focused institutional funds” and company insiders, according to its regulatory filing with the Securities and Exchange Commission (SEC).In addition, it has also retired $17.5 million in debt from Avenue Capital and has entered into a $11.5 million loan agreement with an insider-led investor group. In 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air’s preclinical oncology team and exclusive rights to the intellectual property portfolio for the treatment of solid tumors are currently with Beyond Cancer.Beyond Air has 80% ownership in Beyond Cancer.Beyond Air’s stock is down 77.2% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;

The biopharma company’s earnings were in line with analyst estimates of -$0.28 per share.| Source: Pixabay

Beyond Air Stock Slides After Q2 Earnings Beat, Retail’s Confident

Retail sentiment on the stock turned ‘extremely bullish’ from ‘bullish’ a day ago.

Beyond Air ($XAIR), a medical device and biopharmaceutical company focused on developing treatments for lung diseases, saw its shares rise 6% (2:06 pm ET) ahead of its second-quarter earnings, lifting retail sentiment on Stocktwits.The commercial-stage medical device and biopharmaceutical company is expected to report a net loss per share of $0.28 on revenue of $1.03 million by Wall Street analysts. The company beat EPS estimates last quarter by 14.80%, posting a loss per share of $0.27. It has beaten consensus estimates three times in the last four quarters and re-issued revenue guidance of at least $10 million for FY 2025 in August.Retail sentiment on the company inched up on Monday, rising to ‘bullish’ (67/100) from ‘neutral’ (46/100) a day ago as message volumes rose from ‘low’ to ‘high.’<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_12_at_12_39_59_AM_b3e5e1fde4.png" alt="Screenshot 2024-11-12 at 12.39.59 AM.png" width="1300" height="290"><figcaption>XAIR sentiment meter and message volumes on Nov 11 as of 2:08 pm</figcaption></figure>Many Stocktwits users were seen as hopeful of the company’s positive guidance for the next quarter.<stembedurl>https://stocktwits.com/45IQ/message/591848394</stembedurl>“We are confident in the long-term growth of our optimized LungFit PH system and have received positive feedback from new and existing customers as they realize the clinical benefits the system provides by offering on-demand, ambient air-generated NO compared to legacy cylinder NO systems,” Steve Lisi, Chairman and CEO Beyond Air, said in August.In October, Beyond Air entered a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting firm, to expand access to Beyond Air's LungFit PH system by streamlining entry into Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, IDNs, across the US, The Fly <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=XAIR">reported.</a>XAIR stock is down 73.93% year-to-date, but Stocktwits sentiment suggests retail remains optimistic about the company’s long-term turnaround potential.For updates and corrections, email newsroom@stocktwits.com&nbsp;&nbsp;

Analysts estimate Beyond Air will report losses per share of $0.28.| Source: Pixabay

Beyond Air Stock Rises Ahead Of Earnings: Retail Bullish

Retail sentiment on the company inched up on Monday, rising to ‘bullish’ (67/100) from ‘neutral’ (46/100) a day ago. 

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Beyond Air Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

XAIR
Beyond Air Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest XAIR News

XAIRBeyond Air Inc